a while back, NP or Kelly talked about a number of
Post# of 148175
My assumption is that the FDA, MHRA, Canada, etc. are the only ones with access to the data - but if the data is good, and Pharma knew this, you could easily see some negotiations going on.
Let's just cut a deal for COVID (say $20 a share) with BP, and then we keep the rest of the indications and develop them over time - that works for me